April 11, 2012 -- RayBiotech, Inc. today announced that it has entered into a co-marketing partnership with Innopsys of Carbonne, France to promote the sales of RayBiotech’s G-Series and Quantibody series of antibody arrays and array testing services with Innopsys’ Innoscan laser microarray scanning platforms. The terms of the partnership were not disclosed.
Commenting on the partnership RayBiotech’s President, COO and Co-founder, Rani Huang stated, “We are delighted to formally partner with Innopsys to co-market and promote our antibody arrays and antibody array testing services with Innopsys microarray scanners and laser scanning technologies. This represents the first in a series of partnerships we will pursue in 2012 with private as well as academic and government institutions to drive RayBiotech products and services exposure and acceptance in the research community. The Innopsys Innoscan microarray laser scanning platform is our preferred choice of scanning instrumentation for our G-Series and Quantibody series microarray-based products and services.”
Innopsys CEO Stephane Le Brun added, “We are equally encouraged by this partnership which we hope will be the beginning of a fruitful effort between Innopsys and Raybiotech. Innopsys’ Innoscan scanners will give Raybiotech and their customers the tools they need to obtain their data both quickly and accurately. Innopsys sees proteomics as one of its largest areas of growth, thus we view a partnership with Raybiotech as a solid reinforcement to our already growing presence in this sector. Finally, we believe that this partnership will be of greatest benefit to the end user, giving them easy access to coordinated customer support from both companies.”
About RayBiotech, Inc.
RayBiotech (http://www.raybiotech.com) pioneered the development of antibody and protein array technologies and provides reliable high-throughput platforms for identifying disease mechanisms, screening and validation of novel biomarkers and identification of new drug targets. In 2001 RayBiotech introduced the first commercially available cytokine antibody array. Since then, RayBiotech array products have been featured in hundreds of publications, including some in top-tier journals: Nature, Nature Medicine, Cell, Lancet, PNAS (USA), and many others. Offering more antibody array choices than any of its competitors, RayBiotech has established a leading reputation for the high quality and innovative developments provided to the research community. RayBiotech continues to lead in the development of protein array technologies and is focused on further meeting the needs of clients in translating new knowledge of human biology to improved health. A spin-off from Emory University’s School of Medicine, RayBiotech is privately owned, with headquarters in metropolitan Atlanta (Norcross, GA).
Formed in 1999, Innopsys (www.innopsys.com/) develops, manufactures and sells microarray scanners and associated software for biotechnological & medical research laboratories combining cost-effectiveness with performance. Since 2006, Innopsys has offered a complete range of InnoScan microarray scanners, enabling it to become a leader in its market. Innopsys sells its products in more than 35 countries through its worldwide distribution network and its United States subsidiary in Chicago.
Innovation is the core of Innopsys’ strategy; annually investing 35% of its turnover in R&D. Its own efforts combined with numerous academic and industrial partnerships make Innopsys a company with great potential in the market for the biotech products of tomorrow.
Products are entirely designed and manufactured on site in Carbonne, situated in the Midi-Pyrénées area of France. The Innopsys team is comprised of mostly scientists and engineers and is distinguished by its cutting-edge skills in a variety of scientific and technical fields including optics, micromechanics, onboard electronics, computing, nanotechnology and biology. With the help of several partnerships, two new instruments will be launched in 2012: an infrared fluorescence scanner and an innovative biomolecular microcontact printing system.